Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Flavopiridol is a broad cyclin-dependent kinase inhibitor (CDKI) that induces apoptosis of malignant lymphocytes in vitro and in murine lymphoma models. We conducted a phase I dose-escalation study to determine the maximum tolerated dose (MTD) for single-agent flavopiridol administered on a pharmaco...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Jones, Jeffrey A., Rupert, Amy S., Poi, Ming, Phelps, Mitch A., Andritsos, Leslie, Baiocchi, Robert, Benson, Don M., Blum, Kristie A., Christian, Beth, Flynn, Joseph, Penza, Sam, Porcu, Pierluigi, Grever, Michael R., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4150545/
https://ncbi.nlm.nih.gov/pubmed/23959599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23568
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares